SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: contrarian who wrote (1408)1/6/1998 4:19:00 PM
From: Pseudo Biologist  Read Replies (1) of 1762
 
Contrarian, not sure if this new but I've heard from a couple of sources that Genentech has amassed significant supplies of Rituxan, and supply should not be a problem. I also hear that many many oncologists are enthusiastic about the drug given its mild side effect profile, and, of course, decent activity. If they could (read, get their patients reimbursed by the HMOs or insurance companies), they would use it in a very large portion of low-grade NHL patients, way beyond what the current label says. This is a very easy drug to give when you compare it with radioactive or chemotherapeutic regimes.

On other drugs, one has to keep an eye on the anti-CD4 primatized MAb; many people are nervous about this one. I am awaiting the anti-C40L (aka anti-gp39) drug to enter clinicals; this one should be very interesting. And there is also the topoisomerase small molecule inhibitor they got from PNU; we'll hear something from this one this year.

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News